中国分享抗COVID-19药物治疗的新进展

中国分享抗COVID-19药物治疗的新进展

China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the novel coronavirus disease (COVID-19), according to an official Tuesday.

周二，据官方消息，中国已经完成了抗病毒药物Favipiravir的临床研究，该药物对新型冠状病毒病(COVID-19)表现出良好的临床疗效。

Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference.

中国科技部国家生物技术发展中心主任张新民在新闻发布会上表示，2014年被批准在日本临床使用的流感药物Favipiravir在临床试验中没有出现明显的不良反应。

More than 80 patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, south China's Guangdong Province, including 35 patients taking Favipiravir and 45 patients on a control group. Results showed that patients receiving Favipiravir treatment turned negative for the virus in a shorter time compared with patients in the control group.

在中国南方广东省深圳市第三人民医院，80多名患者参加了临床试验，其中35名患者服用了Favipiravir，45名患者为对照组。结果显示，与对照组相比，接受Favipiravir治疗的患者在较短时间内转为阴性。

A multi-centered randomized clinical study led by the Zhongnan Hospital of Wuhan University also suggested that the therapeutic effect of Favipiravir is much better than that of the control group.

武汉大学中南医院领导的一项多中心随机临床研究也表明，Favipiravir的疗效明显优于对照组。

Favipiravir has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for COVID-19 as soon as possible, Zhang said.

张新民表示，Favipiravir已经被推荐给医疗队，应该尽快被纳入COVID-19的诊断和治疗计划。

A Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the drug and ensure stable supply, Zhang added.

张新民补充说，一家中国制药公司已经获得国家药品监督管理局的批准，可以批量生产该药，并确保稳定的供应。

China is also pushing forward the utilization of some advanced technologies such as stem cell and artificial liver and blood purification in the treatment of severe cases.

中国还在推进利用干细胞、人工肝、血液净化等先进技术治疗重症患者。

Zhang said stem cell therapy proves effective in reducing severe inflammatory reactions caused by COVID-19, as well as reducing lung injury and pulmonary fibrosis in patients.

张新民说，干细胞治疗被证明在减少COVID-19引起的严重炎症反应，以及减少患者的肺损伤和肺纤维化方面是有效的。

China has initiated several clinical research programs on stem cell therapy against COVID-19, including a stem cell drug that has been approved for clinical trial and a mesenchymal stem cell therapy.

中国已经启动了多个针对COVID-19的干细胞治疗的临床研究项目，包括一种已被批准用于临床试验的干细胞药物和一种间充质干细胞治疗。

Stem cell therapy has been used to treat 64 patients in severe and critical condition. Those patients' breathing difficulties were gradually relieved and they were generally cured in eight to 10 days. The therapy also showed advantages in preventing pulmonary fibrosis and improving the long-term prognosis for patients.

应用干细胞治疗危重症64例。患者呼吸困难逐渐缓解，一般在8 ~ 10天内治愈。本疗法在预防肺纤维化和改善患者远期预后方面也有一定的优势。

The Chinese Society for Cell Biology and the Chinese Medical Association have jointly issued a guideline to standardize the clinical research and application of stem cell therapy against COVID-19.

中国细胞生物学学会、中华医学会联合发布《关于规范COVID-19干细胞治疗临床研究和应用的指导意见》。

Zhang said China is trying to use artificial liver and blood purification technology to treat critically ill patients. Patients receiving this treatment have seen reduced levels of inflammatory factors and improvement in chest imaging. Their time on ventilator support has been decreased by an average of 7.7 days and the required ICU monitoring time has been shortened.

张新民说，中国正在尝试使用人工肝和血液净化技术来治疗危重病人。接受这种治疗的患者炎症因子水平降低，胸部影像学改善。平均减少呼吸机支持时间7.7天，缩短了ICU监护时间。